1. |
UK MCA criticised by MPs |
|
Inpharma Weekly,
Volume &NA;,
Issue 1396,
2003,
Page 2-2
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2003
数据来源: ADIS
|
2. |
Management of cancer-related fatigue |
|
Inpharma Weekly,
Volume &NA;,
Issue 1396,
2003,
Page 3-3
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2003
数据来源: ADIS
|
3. |
Role of natriuretic peptides in treatment of heart failure |
|
Inpharma Weekly,
Volume &NA;,
Issue 1396,
2003,
Page 4-4
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2003
数据来源: ADIS
|
4. |
Escitalopram worth it for preventing SAD relapse |
|
Inpharma Weekly,
Volume &NA;,
Issue 1396,
2003,
Page 5-6
L Hunt,
Preview
|
|
摘要:
Social anxiety disorder (SAD) is a prevalent, chronic psychiatric disorder characterised by a high level of comorbidity. US costs associated with anxiety disorders, of which SAD is the most prevalent, are estimated at nearly $US47 billion per year. Escitalopram, a selective serotonin reuptake inhibitor (SSRI), demonstrates long-term efficacy and is well tolerated among patients with SAD, according to the results of a study presented at the 156th Annual Meeting of the American Psychiatric Association (APA) [San Francisco, California, US; May 2003].1A second study presented at the meeting concluded that escitalopram enhances quality of life (QoL), and appears to be cost effective, in the prevention of relapse in patients with SAD.2Both studies were supported by funding from H Lundbeck A/S.
ISSN:1173-8324
出版商:ADIS
年代:2003
数据来源: ADIS
|
5. |
Patient noncompliance with medication accounts for more than $US100 billion in excess healthcare costs per year in the US, |
|
Inpharma Weekly,
Volume &NA;,
Issue 1396,
2003,
Page 6-6
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2003
数据来源: ADIS
|
6. |
Newer HCV treatments"reasonably cost effective" |
|
Inpharma Weekly,
Volume &NA;,
Issue 1396,
2003,
Page 7-7
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2003
数据来源: ADIS
|
7. |
Vaccination strategies for T-cell induction against malaria |
|
Inpharma Weekly,
Volume &NA;,
Issue 1396,
2003,
Page 8-8
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2003
数据来源: ADIS
|
8. |
BOND: Cetuximab a promising new agent for colorectal cancer |
|
Inpharma Weekly,
Volume &NA;,
Issue 1396,
2003,
Page 9-10
RM Poole,
Preview
|
|
摘要:
The investigational IgG1 monoclonal antibody cetuximab [`Erbitux'] provides significant benefits for patients with metastatic colorectal cancer, according to data presented at the 39th Annual Meeting of the American Society of Clinical Oncology (ASCO) [Chicago, US; May-June 2003]. Results from a BOND, a phase II study involving more than 300 patients with irinotecan-refractory colorectal cancer, showed that treatment with cetuximab plus irinotecan delayed disease progression by approximately 4 months, with stabilisation or improvement of disease achieved in more than half of the patients. Monotherapy with cetuximab was less effective than combination therapy with irinotecan, but was better tolerated and may provide an option for patients experiencing severe adverse events associated with irinotecan. A smaller study presented at the ASCO meeting suggested that cetuximab plus a biweekly regimen containing fluorouracil, irinotecan and folinic acid was effective as first-line therapy for colorectal cancer.
ISSN:1173-8324
出版商:ADIS
年代:2003
数据来源: ADIS
|
9. |
Tifacogin not useful for severe sepsis |
|
Inpharma Weekly,
Volume &NA;,
Issue 1396,
2003,
Page 11-11
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2003
数据来源: ADIS
|
10. |
Adjunctive pregabalin effective for partial seizures |
|
Inpharma Weekly,
Volume &NA;,
Issue 1396,
2003,
Page 12-12
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2003
数据来源: ADIS
|